

Drug Policy:

Ayvakit™ (avapritinib)

POLICY NUMBER UM ONC_1378	SUBJECT Ayvakit™ (avapritinib)		DEPT/PROGRAM UM Dept	PAGE 1 of 3
DATES COMMITTEE REVIEWED 02/12/20, 12/09/20, 08/11/21, 11/15/21, 05/11/22, 07/13/22, 04/12/23, 07/12/23, 07/10/24	APPROVAL DATE July 10, 2024	EFFECTIVE DATE July 26, 2024	COMMITTEE APPROVAL DATES 02/12/20, 12/09/20, 08/11/21, 11/15/21, 05/11/22, 07/13/22, 04/12/23, 07/12/23, 07/10/24	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT		
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Ayvakit (avapritinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

B. Gastrointestinal Stromal Tumor (GIST)

1. The member has unresectable or metastatic GIST with a documented platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations, and Ayvakit (avapritinib) may be used as monotherapy.

C. Systemic Mastocytosis (SM)

1. Ayvakit (avapritinib) will be used as monotherapy in a member with indolent and aggressive/advanced systemic mastocytosis (AdvSM) [e.g., systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)] and the member's platelet count is greater than or equal to $50 \times 10^9/L$ prior to start of therapy.

III. EXCLUSION CRITERIA

- A. Ayvakit (avapritinib) is being used after disease progression with the same regimen.
- B. Use of Ayvakit (avapritinib) in PDGFRA wild type GIST.
- C. Concurrent use of another tyrosine kinase inhibitor (e.g., imatinib, sunitinib, regorafenib, sorafenib, dasatinib, or pazopanib).
- D. Dosing exceeds single dose limit of Ayvakit (avapritinib) 300 mg (for GIST), 200 mg (for Advanced SM) and 25 mg (for Indolent SM).
- E. Treatment exceeds the maximum limit of 30 (25 mg), 30 (50 mg), 90 (100 mg), 30 (200 mg), or 30 (300 mg) tablets/month.
- F. Investigational use of Ayvakit (avapritinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- C. None

VII. REFERENCES

- A. Gotlib J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. *Nat Med.* 2021 Dec;27(12):2192-2199.
- B. DeAngelo DJ, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. *Nat Med.* 2021 Dec;27(12):2183-2191.
- C. Gotlib J, et al. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. *NEJM Evid* 2023;2(6).
- D. Jones RL, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. *Eur J Cancer.* 2021 Mar;145:132-142.
- E. Blay JY, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2020 Jul;21(7):923-934.
- F. Ayvakit prescribing information. Blueprint Medicines Corporation, Cambridge, MA 2023.
- G. Clinical Pharmacology Elsevier Gold Standard 2023.
- H. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2023.
- I. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2022.
- J. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2023.
- K. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol.* 2014 Apr 20;32(12):1277-80.
- L. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.